Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial) Meeting Abstract
| Authors: | De Wit, R.; Fizazi, K.; Jinga, V.; Efstathiou, E.; Fong, P. C. C.; Wirth, M.; Suzuki, K.; Moran, S.; Wang, L.; Akaza, H.; Nelson, J.; Scher, H. I.; Dreicer, R.; Borgstein, N. G.; Saad, F. |
| Abstract Title: | Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613203402 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.5008 |
| Notes: | Meeting Abstract: 5008 -- Source: Wos |
